GlaxoSmithKline PLC has its eye on the horizon, which means on its growing oncology pipeline, not its maturing respiratory portfolio.
Management spent most of the company’s fourth quarter sales and earnings call Feb. 6 highlighting new pipeline opportunities, particularly in...